<DOC>
	<DOCNO>NCT00967291</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , mitomycin C ifosfamide , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give mitomycin C together ifosfamide work treat patient metastatic pancreatic cancer .</brief_summary>
	<brief_title>Mitomycin C Ifosfamide Treating Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To assess therapeutic activity mitomycin C ifosfamide combination , term progression-free survival rate 6 month , patient metastatic stage IV adenocarcinoma pancreas . OUTLINE : Patients receive mitomycin C IV day 1 ifosfamide IV day 1-3 . Courses repeat every 4 week 6 course absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma pancreas Stage IV disease Metastatic disease Prior treatment gemcitabinebased chemotherapy , also adjuvant setting , progressionfree survival ≤ 12 month Measurable disease accord RECIST criterion No symptomatic brain metastasis PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % ( 80100 % patient &gt; 70 year age ) Adequate bone marrow , liver , kidney function Not pregnant nursing No prior concurrent malignancy except surgically cure carcinoma situ cervix , basal cell squamous cell carcinoma skin , neoplasms evidence disease ≥ 5 year No severe comorbidities could compromise safety , include follow : Cardiac failure Cardiac arrhythmia Prior myocardial infarction within past 4 month History psychiatric disability PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior mitomycin C ifosfamide No concurrent treatment experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>acinar cell adenocarcinoma pancreas</keyword>
	<keyword>duct cell adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
</DOC>